December 3,Paris, France – Ipsen announces the acquisition of a product developed by Biomunex PharmaceuticalsTheMAIT cell engager (TCE) BMX-502 Global Exclusive License Agreement. BMX-502 is a bispecific antibody that engages and activates a cytotoxic T-cell subset known as mucosal-associated invariant T cells (MAIT cells) and targets the GPC3 tumor antigen to kill cancer cells. GPC3 is a clinically validated target highly expressed in several cancer types. MAIT cells are distributed throughout the body and are highly enriched in many specific tissues, particularly in mucosal and barrier tissues. BMX-502 offers a promising approach for treating tumors in these tissues.
According to the terms of the agreement, Biomunex will completeIND-enablingPlan.Ipsen will be responsible for Phase I preparation activities, including the submission of the Investigational New Drug (IND) application, as well as all subsequent clinical development and global commercialization activities.Biomunex is eligible to receive up to $610 million in upfront payments, depending on successful development, regulatory, and commercial milestones, as well as tiered global sales royalties.
BMX-502, developed using Biomunex's proprietary BiXAb technology, selectively binds to MAIT cells and leverages their unique properties to maximize anti-tumor activity. MAIT engager (MAIT engagers) Should overcome the currentpan-T cell engager therapiesSome limitations, including the activation of regulatory T cells and cytokine release syndrome, are difficult for patients to manage and pose a significant burden on the healthcare system. Classic types associated with specific tumors.pan-T cell engager therapiesIn comparison,MAIT engagersPossibly providing a more robust therapeutic window.Mary Jane Hinrichs, Senior Vice President and Head of Early Development at Ipsen, stated:"As we continue to use a science-first approach to collaborate across the ecosystem to expand Ipsen's portfolio, we believe BMX-502 is a strong addition with best-in-class potential in solid tumors. This newMAIT engagersThe plan will supplement our existing TCE portfolio as we leverage next-generation T-cell engagers to overcome therapeutic challenges, including dose-limiting toxicity, bringing revolutionary new drugs to solid tumor patients worldwide.Dr. Pierre Emmanuel Gerard, founder, president and CEO of Biomunex, said:"The agreement reached with an innovative oncology company like Ipsen demonstrates Biomunex'sMAIT-engagerMethodological relevance: Biomunex is the first company in the world to identify the high therapeutic potential of MAIT cells in cancer treatment. It also demonstrates the added value of our first-in-class BiXAb platform in rapidly generating innovative and promising bispecific antibodies. We believe that ourMAIT-engager"This represents a new step in the development of disruptive immune thawing agents for cancer treatment. We look forward to initiating and supporting the development of BMX-502 with Ipsen."
Follow the official account below to explore the world with you!
